RCS - Theracryf PLC - Publication of peer reviewed data

TheracryfAnnouncement

11/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241111:nRSK6461La&default-theme=true

RNS Number : 6461L  Theracryf PLC  11 November 2024

RNS REACH

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Publication of peer reviewed data on healthy volunteer pharmacokinetic study

of SFX-01 novel tablet in Advances in Therapy

Alderley Park, UK - 11 November 2024: TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on oncology and neuropsychiatry
announces publication of the pharmacokinetic and safety/tolerability data on
lead clinical asset SFX-01 from its Ph1b healthy volunteer study in the peer
reviewed journal, Advances in Therapy.

The publication, which can be found here
(https://link.springer.com/article/10.1007/s12325-024-03018-1) , reports on
the findings of the study which aimed to investigate how the new SFX-01
enteric-coated tablet formulation performed and how sulforaphane released from
the novel formulation was metabolised in the bloodstream of the healthy
volunteers and subsequently excreted.

As announced previously in August 2023, the data from the study demonstrated
that the Company's new enteric coated tablet formation of lead asset SFX-01
was shown to perform as designed, delivering drug and active metabolites, as
well as being safe and well tolerated.

The publication concluded that the data from the phase 1 randomized,
double-blinded, placebo-controlled, dose-escalation study demonstrated:

·    SFX-01 was well tolerated over 7 days at the doses evaluated, with
most side-effects being mild and transient in nature.

·    The pharmacokinetic properties of the SFX-01 tablet formulation were
in line with expectations, suggesting that enteric coating and stabilization
of sulforaphane delivers levels of SFN and metabolites in the range where
biological activity is observed.

This publication was authored by TheraCryf's Chief Medical Officer, Dr Glen
Clack, and Vice-President, Project Management, Dr Nicholas Mallard, along with
consultants to the Company.

Dr Helen Kuhlman, TheraCryf's CBO, commented:

"We are pleased to see our data published in a peer reviewed academic journal.
Our study is a definitive examination of sulforaphane's pharmacokinetics from
our proprietary enteric coated tablet and provides a detailed analysis of the
delivery and handling of sulforaphane from SFX-01 tablets by the body."

Dr Glen Clack, TheraCryf's CMO added:

"These data prepare us well for future studies, in particular glioblastoma
patients in our grant funded collaboration with the Erasmus Medical Centre
Rotterdam, NL."

-Ends-

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Vigo Consulting                                             +44 (0)20 7390 0231
 Rozi Morris
theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(http://www.theracryf.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADBBDBRUBDGSG